Company intelligence / Profile preview

Vitastiq

Ownership: Private
Development stage: Commercial

Overview

Vitastiq has developed and commercialized the world’s first personal vitamin tracker using Electroacupuncture According to Voll (EAV) methodology. A clinical study comparing its readings to blood tests showed accuracy well above the established 70% target. The device tracks trends in 26 vitamins and minerals via a non-invasive pen connected to an app.

Therapeutic areas: Metabolic DisordersOther
Modalities: DeviceNon-pharmacological therapy (electroacupuncture-based measurement)
Industry: Physiological Monitoring

Partnerships

Clinical study conducted with Vizera CRO; no major pharma/biotech partnerships disclosed

Beyond the preview

Go deeper on Vitastiq.

Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from trial design and recruitment through results.

Trial phase
Status
Readouts

Licensing & deals

Explore licensing agreements, acquisitions, and the assets behind each deal.

Partners
Deal terms
Milestones

Funding history

Trace financing activity and the investors behind a company’s development.

Funding rounds
Investors
Capital raised

Competitive landscape

Compare peer pipelines by target, modality, and therapeutic area.

Peer companies
Targets
Pipeline overlap

Technologies & patents

Explore technology platforms and the patent landscape around relevant assets.

Platforms
Patents
Assignees

Research & analysis

Connect company news and source material to the questions you’re investigating.

Company news
Sources
Analysis

Bring the full picture into focus.

See how Gosset can support your research on Vitastiq.

Explore the full profile